Get the Stockscreener App
14.30
9.16%
1.20
10 X Genomics Inc stock is traded at $14.30, with a volume of 3.44M.
It is up +9.16% in the last 24 hours and up +10.08% over the past month.
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The company's integrated solutions include instruments, consumables, and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. Its product offerings include a Chromium platform comprising microfluidic chips and related consumables, Chromium X series, Visium and Xenium platforms, and others, which are predominantly used for the study of biological components. Geographically, the company derives maximum revenue from the United States and the rest from Americas (excluding the United States), Europe, Middle East and Africa, China, and Asia-Pacific (excluding China).
See More
Previous Close:
$13.10
Open:
$13.16
24h Volume:
3.44M
Relative Volume:
0.95
Market Cap:
$1.64B
Revenue:
$631.73M
Net Income/Loss:
$-239.78M
P/E Ratio:
-7.0792
EPS:
-2.02
Net Cash Flow:
$-33.45M
1W Performance:
+7.04%
1M Performance:
+10.08%
6M Performance:
+31.19%
1Y Performance:
-35.73%
1-Day Range:
$13.11
$14.30
1-Week Range:
$12.93
$14.30
52-Week Range:
$6.78
$24.76
10 X Genomics Inc Stock (TXG) Company Profile
Name
10 X Genomics Inc
Sector
Industry
Phone
(925) 401-7300
Address
6230 STONERIDGE MALL ROAD, PLEASANTON, CA
Compare TXG with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TXG
10 X Genomics Inc
|
14.30 | 1.68B | 631.73M | -239.78M | -33.45M | -2.02 |
|
VEEV
Veeva Systems Inc
|
290.86 | 46.10B | 2.86B | 780.66M | 1.19B | 4.72 |
|
TEM
Tempus Ai Inc
|
80.52 | 13.63B | 803.32M | -709.10M | -212.68M | -7.8003 |
|
DOCS
Doximity Inc
|
67.74 | 12.35B | 550.17M | 201.35M | 232.07M | 1.00 |
|
HQY
Healthequity Inc
|
89.82 | 7.74B | 1.15B | 96.70M | -161.99M | 1.09 |
|
WAY
Waystar Holding Corp
|
36.24 | 6.32B | 906.14M | -52.62M | 89.62M | -0.3621 |
10 X Genomics Inc Stock (TXG) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-13-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Sep-03-24 | Initiated | Leerink Partners | Outperform |
| Jul-22-24 | Upgrade | Jefferies | Hold → Buy |
| Jul-18-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-10-24 | Downgrade | Deutsche Bank | Buy → Hold |
| Jun-27-24 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jun-25-24 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-03-24 | Resumed | Jefferies | Hold |
| May-01-24 | Downgrade | TD Cowen | Buy → Hold |
| Dec-14-23 | Initiated | Guggenheim | Buy |
| Dec-13-23 | Initiated | Wolfe Research | Outperform |
| Dec-12-23 | Upgrade | BofA Securities | Underperform → Neutral |
| Jul-05-23 | Resumed | JP Morgan | Overweight |
| May-10-23 | Initiated | Barclays | Overweight |
| Mar-31-23 | Initiated | Stephens | Overweight |
| Feb-02-23 | Initiated | UBS | Neutral |
| Dec-14-22 | Initiated | Deutsche Bank | Buy |
| Aug-18-22 | Downgrade | Goldman | Neutral → Sell |
| Jul-25-22 | Initiated | Canaccord Genuity | Buy |
| Jul-15-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Jul-15-22 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Sep-14-21 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-15-21 | Initiated | William Blair | Outperform |
| Dec-02-20 | Initiated | Goldman | Neutral |
| Sep-09-20 | Initiated | Morgan Stanley | Overweight |
| Jul-10-20 | Initiated | Stifel | Buy |
| Mar-05-20 | Initiated | Guggenheim | Buy |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Oct-07-19 | Initiated | BofA/Merrill | Buy |
| Oct-07-19 | Initiated | Cowen | Outperform |
| Oct-07-19 | Initiated | JP Morgan | Overweight |
| Sep-24-19 | Initiated | Evercore ISI | Outperform |
View All
10 X Genomics Inc Stock (TXG) Latest News
10x Genomics Launches Xenium Protein, Advancing Spatial Biology by Enabling Same-Cell RNA and Protein Analysis - BioSpace
Is 10x Genomics Inc. a play on infrastructure spendingEarnings Overview Summary & Long-Term Capital Growth Strategies - thegnnews.com
10x Genomics launches Xenium Protein for integrated RNA-protein analysis - Investing.com
First-Ever Single-Run RNA and Protein Analysis: 10x Genomics Revolutionizes Spatial Biology Research - Stock Titan
Quant Strategy Flags 10x Genomics Inc. for Entry2025 EndofYear Setup & Short-Term Trading Opportunity Alerts - newsyoung.net
10x Genomics and A*STAR Genome Institute of Singapore Launch TISHUMAP Study to Advance AI-Driven Drug Target Discovery - ADVFN Brasil
Custom Dashboard Highlights 10x Genomics Inc. Price MomentumJuly 2025 Sector Moves & Daily Risk Controlled Trade Plans - beatles.ru
10x Genomics (TXG) Is Up 8.7% After Return to Profit and Tariff-Driven Sales Surge - simplywall.st
Cathie Wood's ARK buys Qualcomm and 10X Genomics stock - MSN
Analyzing 10x Genomics Inc. with multi timeframe chartsWeekly Market Outlook & Momentum Based Trading Ideas - Newser
Relative strength of 10x Genomics Inc. in sector analysisJuly 2025 Spike Watch & Community Consensus Trade Signals - Newser
What to do if you’re stuck in 10x Genomics Inc.July 2025 Price Swings & High Return Trade Guides - Newser
Real time alert setup for 10x Genomics Inc. performanceQuarterly Profit Summary & AI Enhanced Trading Signals - Newser
Can 10x Genomics Inc. stock double in the next yearSwing Trade & Smart Investment Allocation Insights - sundaytimes.kr
Market reaction to 10x Genomics Inc.’s recent newsWeekly Investment Report & Weekly Watchlist for Hot Stocks - Newser
Is 10x Genomics Inc. a potential multi baggerGap Down & Real-Time Volume Surge Alerts - newsyoung.net
10x Genomics’ (TXG) “Sell (E+)” Rating Reiterated at Weiss Ratings - Defense World
What makes 10x Genomics Inc. stock price move sharplyPortfolio Performance Report & Free Accurate Trade Setup Notifications - Newser
Building trade automation scripts for 10x Genomics Inc.Trade Volume Summary & Free Growth Oriented Trading Recommendations - Newser
10x Genomics Reports Second Quarter 2025 Financial Results - ADVFN Brasil
10x Genomics Reports First Quarter 2025 Financial Results - ADVFN Brasil
10x Genomics to Acquire Scale Biosciences - SynBioBeta
Brookdale, Evolent Health, Fortrea, 10x Genomics, and Organon Stocks Trade Up, What You Need To Know - Yahoo Finance
10X Genomics’ SWOT analysis: genomics firm’s stock faces funding headwinds By Investing.com - Investing.com Nigeria
10X Genomics’ SWOT analysis: genomics firm’s stock faces funding headwinds - Investing.com
Earnings Beat: 10x Genomics, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models - 富途牛牛
10x Genomics (NASDAQ:TXG) Given New $17.00 Price Target at Morgan Stanley - Defense World
10X Genomics Q2 Earnings Call Highlights: Balancing Growth and Challenges with Strong China Performance and Favorable Bruker Settlement - AInvest
10x Genomics (NASDAQ:TXG) Given Consensus Rating of “Hold” by Brokerages - Defense World
Price Floor Holding on 10x Genomics Inc. — Rebound PossibleBuy Alerts With Low Risk Confirmation Noted - sundaytimes.kr
10X Genomics Balances Growth and Challenges in Earnings Call - TipRanks
Does 10x Genomics Inc. qualify in momentum factor screeningEntry Zone Watchlist With Momentum Focus - Newser
Tandem Diabetes, iRhythm, agilon health, Fortrea, and 10x Genomics Shares Skyrocket and Plummet, What You Need To Know - Yahoo Finance
Does 10x Genomics Inc. offer margin of safetyFree Weekly Earnings Watchlist - thegnnews.com
10x Genomics, Inc. (NASDAQ:TXG) Q2 2025 Earnings Call Transcript - Insider Monkey
Zacks.com featured highlights include Tsakos Energy Navigation Limited, 10x Genomics, Pan American Silver, Wolverine World Wide and Interface - Yahoo Finance
Will Breakout in 10x Genomics Inc. Sustain Through Next WeekIntraday Trend Analysis for Fast Gains Released - beatles.ru
Is 10x Genomics Inc. stock reversal real or fakeForecasting Stock Moves with AI Insights - Newser
10x Genomics (NASDAQ:TXG) Receives “Overweight” Rating from Barclays - Defense World
Chart Analysts Warn of Resistance Near 10x Genomics Inc. PriceDaily Smart Money Movement Monitor Activated - beatles.ru
10x Genomics Sees Strong Growth with Q2 Results, Strategic Acquisition, and Optimistic Outlook - AInvest
Transcript : 10x Genomics, Inc., Q2 2025 Earnings Call, Aug 07, 2025 - MarketScreener
10x Genomics (NASDAQ:TXG) Shares Gap Up on Better-Than-Expected Earnings - Defense World
10x Genomics (NASDAQ:TXG) Upgraded to Buy at Wall Street Zen - Defense World
Why 10x Genomics (TXG) Is Down 6.0% After Tariff-Driven Q2 Revenue Surge and Guidance Update - simplywall.st
10x Genomics shares rise 1.71% after-hours following Q2 revenue beat and Deutsche Bank price target adjustment. - AInvest
10x Genomics: UBS maintains a 'Neutral' Rating, The Target Price is $13 - AInvest
10x Genomics: UBS maintains Neutral rating, raises PT to $13 from $12. - AInvest
10x Genomics shares fall 4.65% intraday after reporting Q2 revenue of $172.9M, below analyst estimates of $139.4M. - AInvest
10x Genomics (NASDAQ:TXG Shareholders Incur Further Losses as Stock Declines 4.8% This Week, Taking Five-year Losses to 88% - 富途牛牛
Why 10x Genomics (TXG) Stock Is Falling Today - Yahoo Finance
10 X Genomics Inc Stock (TXG) Financials Data
Revenue
Net Income
Cash Flow
EPS
10 X Genomics Inc Stock (TXG) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Hindson Benjamin J. | See Remarks |
May 22 '25 |
Sale |
8.30 |
7,485 |
62,120 |
448,374 |
| Taich Adam | Chief Financial Officer |
May 22 '25 |
Sale |
8.30 |
4,044 |
33,562 |
331,588 |
1.72%
0.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):